Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P et al. · Lancet (London, England) · PMID 42250575
Study summary
Main finding
Retatrutide groups had greater reductions in HbA1c and body weight than placebo. Gastrointestinal events were the most frequent adverse events, and some participants stopped treatment because of adverse events.
40-week randomized placebo-controlled trial in 537 adults
How the study was set up
A randomized, blinded phase 3 trial enrolled 537 adults with diabetes inadequately controlled by diet and exercise, comparing retatrutide with placebo over 40 weeks.
What the researchers measured
HbA1c change at week 40 was primary; body-weight change, adverse events, and treatment discontinuation were also assessed.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
Glucose and weight improved relative to placebo, with gastrointestinal events most frequent. The population, follow-up, and investigational formulation limit application beyond this trial.
What this does not establish
This trial studied a controlled investigational formulation and selected adults with type 2 diabetes. It does not establish every long-term outcome or the identity and safety of retail research products.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.
Publication indexing
Journal Article · Randomized Controlled Trial · Clinical Trial, Phase III · Multicenter Study · Research Support, Non-U.S. Gov't